Gelteq Limited (NASDAQ:GELS – Get Free Report) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 120,948 shares, a growth of 224.2% from the April 30th total of 37,312 shares. Based on an average daily trading volume, of 274,919 shares, the short-interest ratio is presently 0.4 days. Approximately 1.1% of the company’s stock are short sold.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings downgraded Gelteq from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.
Get Our Latest Report on Gelteq
Gelteq Price Performance
Institutional Trading of Gelteq
A hedge fund recently bought a new stake in Gelteq stock. Susquehanna International Group LLP acquired a new stake in shares of Gelteq Limited (NASDAQ:GELS – Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned about 0.44% of Gelteq at the end of the most recent reporting period.
About Gelteq
Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc is based in NEW YORK.
Read More
- Five stocks we like better than Gelteq
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Gelteq Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelteq and related companies with MarketBeat.com's FREE daily email newsletter.
